Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
Sponsor: AstraZeneca
Summary
This is a prospective, open label, multi-center, interventional study to assess the safety and efficacy of Druvalumab plus Tremelimumab as first-line treatment in Chinese patients with unresectable hepatocellular carcinoma.
Official title: An Open-label, Multi-center Phase IIIb Study of Durvalumab and Tremelimumab as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
210
Start Date
2023-02-22
Completion Date
2025-03-31
Last Updated
2025-02-07
Healthy Volunteers
No
Conditions
Interventions
Durvalumab
Durvalumab IV (intravenous infusion)
Tremelimumab
Tremelimumab IV (intravenous infusion)
Locations (32)
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Changsha, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Fuzhou, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Guangzhou, China
Research Site
Hangzhou, China
Research Site
Harbin, China
Research Site
Jinan, China
Research Site
Nanjing, China
Research Site
Nanjing, China
Research Site
Nanjing, China
Research Site
Ningbo, China
Research Site
Shanghai, China
Research Site
Shanghai, China
Research Site
Shenyang, China
Research Site
Tianjin, China
Research Site
Tianjin, China
Research Site
Tianjin, China
Research Site
Wenzhou, China
Research Site
Wuhan, China
Research Site
Wuhan, China
Research Site
Xi'an, China
Research Site
Zhangjiagang, China
Research Site
Zhengzhou, China
Research Site
Zhengzhou, China